Active	Status	Sponsor type	Region	Phase	Filter
3 Active 7 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McCarthy, Helen
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia	Recruiting	2/3	148	Europe	Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib	University College, London, Janssen-Cilag Ltd.	Waldenstrom Macroglobulinemia	03/30	03/30
PembroWM, NCT03630042 / 2018-001767-23: Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia	Completed	2	17	Europe	Pembrolizumab, Rituximab	University College, London, Merck Sharp & Dohme LLC	Waldenstrom Macroglobulinemia	09/21	02/24
REPAIR-MDS, NCT04997811: Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes	Recruiting	2	120	Europe	Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol	Prof. Janet Dunn, Blood Cancer UK, Dudley Group NHS Foundation Trust, University of Birmingham, University of Manchester, King's College Hospital NHS Trust	Myelodysplastic Syndromes (MDS)	01/25	06/25
Waltham, Mathew
No trials found
McLaughlin, Simon
No trials found
Efford, Christopher
No trials found
Olateju, Tolulope
No trials found